Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Noramco.

    Client Virtual Booth

    NORAMCO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    • Buprenorphine

    • Buprenorphine Hydrochloride

    • Gamma-Hydroxybutyric Acid

    • Lisdexamfetamine Dimesylate

    • Sodium Oxybate

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    OTHER PRODUCTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Normaco
    Noramco
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    500 Swedes Landing Rd, Wilmington, DE 19801
    Telephone
    Telephone
    +1 3026523840
    Client Email
    Email
    aambrosi@Noramco.com
    Client Website
    Website
    https://www.noramco.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/noramco-inc-/
    Twitter
    Twitter
    Contact Info
    Others

    Full View ScreenFull Screen View
    • Development Update
    Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

    Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide

    Details:

    Methylnaltrexone bromide is the active ingredient in Relistor®, an FDA-approved prescription medication indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic pain.


    Lead Product(s): Methylnaltrexone Bromide

    Therapeutic Area: Gastroenterology Product Name: Relistor

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 01, 2022

    Noramco

    CPhI North America

    Attending

    envelop Contact Supplier

    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

    Details:

    Under the agreement, Purisys will support an IND filing process, including providing all necessary and related information concerning Chemistry Manufacturing and Controls (CMC) in the form of a comprehensive technical package to be presented to the FDA regarding RCC-33.


    Lead Product(s): RCC-33

    Therapeutic Area: Oncology Product Name: RCC-33

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: CNBX Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement November 04, 2021

    Noramco

    CPhI Japan

    Not Confirmed

    envelop Contact Supplier
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Access Website

    Contact Supplier

    View Presentation

    Normaco

    CPhI North America

    Attending

    envelop Contact Supplier

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search